• Journal of Pharmaceutical Investigation
• /
• v.18 no.1
• /
• pp.15-21
• /
• 1988

An inclusion complex of phenytoin (PT) with ${\beta}-cyclodextrin\;({\beta}-CyD)$ in molar ratio of 1 : 1 was prepared, and the interaction between host and guest molecules was confirmed by infrared spectrometry, differential scanning calorimetry and X-ray diffractometry. Suppositories were prepared by the fusion method. PT and $PT-{\beta}-CyD$ complex were added to PEG 1540 and Witepsol H-15 under the vigorous stirring at $40^{\circ}C$. Content uniformity was tested for different formulations of the PT suppositories. The release rates were dependent on the K.P. V dissolution apparatus and the dialyzing tubing method. Then, the release rates were increased in the following order: $PT-{\beta}-CyD$ complex in PEG 1540>PT in PEG 1540>$PT-{\beta}-CyD$ complex in Witepsol H-15>PT in Witepsol H-15. The area under the curve and maximum blood concentration after rectal administration were increased in the following order: $PT-{\beta}-CyD$ complex in PEG 1540>PT in PEG 1540>$PT-{\beta}-CyD$ complex in Witepsol H-15>PT in Witepsol-15.

• YAKHAK HOEJI
• /
• v.35 no.3
• /
• pp.197-202
• /
• 1991

In order to study drug release from the suppository, three types of hollow suppositories and one conventional suppository were prepared using indomethacin(IDM) as a model drug and Witepsol H-15 as a base. The 4 types of suppository prepared are as follows: type I, conventional suppository containing 50 mg of IDM powder, type II, hollow supository containing 50 mg of IDM powder in the cavity, type III, hollow suppository containing 25 mg of IDM powder in the base and IDM microcapsules (25 mg as IDM powder) in the cavity, and type IV, hollow suppository containing IDM microcapsules (25 mg as IDM powder) in the base and 0.5 ml of 5%(w/v) IDM-PEG 300 solution in the cavity. The drug amount released(%) from type II and I within 24 hrs was 46.7% and 66.9%, respectively. Comparing with the drug amount released from four types of suppository within initial 2 hrs and 24 hrs, that of type IV was high as 32.7% and 76.6%, respectively. IDM-ethycellulose microcapsules passed through 270 mesh sieve and the IDM content was 20.95%.

• Journal of Pharmaceutical Investigation
• /
• v.23 no.3
• /
• pp.127-132
• /
• 1993

The effect of omeprazole (OPZ) suppository on rat rectal mucosa was investigated microscopically. The suppository was prepared with Witepsol H15 base by molding method. Rectal irritation was evaluated according to defined pathological features. The suppository produced a slight damage to the rectal mucosa at 1 hr after the interectal administration, which was almost completely recovered within 24 hr. The damage was not due to OPZ but due to suppository base, Witepsol H15, itself, since Witepsol H15 suppository without OPZ produced the same damage. Therefore, it was concluded that OPZ itself has no rectal mucosa-irritating effect and thus can be developed as a suppository dosage form without any further toxicity problems.

• YAKHAK HOEJI
• /
• v.37 no.4
• /
• pp.370-382
• /
• 1993

In order for formulation of rectal containing OMZ, the OMZ suppositories were prepared using water-soluble base, PEG 4000 base and oil-soluble base, Witepsol H 15. Chemical stability of OMZ in suppositories was increased when Witepsol H 15 was used as a suppository base and arginine was added as a stabilizer. The decomposition of OMZ in suppository bases followed the first-order kinetics and their rate constants were 0.11 day $^{1}(t_{1/2}$=/6.25 days) for Witepsol H 15 suppository and 0.48 day $^{1}(t_{1/2}$=/1.43 days) for PEG 4000 suppository, respectively. On the other hand, the decomposition rate constants of Witepsol suppository and PEG suppository stabilized with arginine were 3.89$\times$10$^{-3}$(t$_{1/2}$=171.1 days) and 8.76$\times$10$^{-3}$ day $^{1}(t_{1/2}=79.9 days), respectively. Shelf-lives of the Witepsol and PEG suppositories stabilized with arginine were t$_{90%}$=291.8 days and t$_{90%}$=282.1 days at $35^{\circ}C$ and 75% RH, respectively. The dissolution test of OMZ suppositories was performed by rotating dialysis cell(RDC) method and the release rate constant was calculated by the simplified Higuchi's equation, Q'=K' t$^{1/2}$. Dissolution of OMZ from suppositories was augmented as arginine was added, particle size of OMZ was reduced and a suitable surfactant such as SLS was added. RDC method was more appropriate and available than Paddle method to evaluate the dissolution rate of lipophilic-base suppositoies. Arginine was found to be a very useful exipient for the enhancement of stability and dissolution of OMZ in suppositories.

• Journal of Pharmaceutical Investigation
• /
• v.20 no.3
• /
• pp.153-159
• /
• 1990

To increase the solubility of fentiazac which is used widely as a non-steroidal antiinflammatory drug, its inclusion complex and suppositories were prepared and studied. Inclusion complexes of fentiazac with ${\beta}-cyclodertin$ $({\beta}-CyD)$ were prepared by four diffrent methods; coprecipitation method, kneading method, solvent evaporation method, freeze drying method. Suppositories of $fentiazac/{\beta}-CyD$ with PEG 1500 and Witepsol H-15 were prepared by solvent evaporation method and freeze drying method. Inclusion complex formation of fentiazac with ${\beta}-CyD$ was ascertained by powder X-ray diffractometry, differential scanning calorimetry and IR spectroscopy. The dissolution rate of fentiazac from the inclusion complex increased in distilled water and KP 2nd disintegration test fluids (pH 6.8) but extemly decreased in KP 1st disintegration test fluid (pH 1.2). Inclusion complexes prepared by freeze drying method and solvent evaporation method were similar. Freeze drying method seemed to be suitable for preparation of complex with most higher dissolution rate but coprecipitation method seemed not to be suitable. The dissolution rate of fentiazac increased markedly by ${\beta}-CyD$ complexation. The release rates of suppositories increased in the following order. Complex prepared by freeze dying method in PEG 1500 > complex prepared by solvent evaporation method in PEG 1500 > fentiazac in PEG 1500 > complex prepared by freeze dying method in Witepsol H-15 > complex prepared by solvent evaporation method in Witepsol H-15 > fentiazac in Witepsol H-15.

• Korean Journal of Clinical Pharmacy
• /
• v.8 no.2
• /
• pp.143-146
• /
• 1998

Acetaminophen (APAP) suppositories with active ingredients, i.e., polyethylene glycol (PEG), Witepsol H-15 (WH), were prepared for hospital use and investigated on their drug release characteristics and pharmacokinetics. WH was employed as oil-soluble base with an aim of reducing fragility and mucosa irritancy that are common drawbacks found in PEG suppositories. Also hollow type suppository was tried as compared with conventional type suppository. Drug release tests revealed that in most formulations, more than $80\%$ of loaded APAP were released within 20 minutes, except for APAP-WH hollow type suppositories. Significant differences in the plasma concentration profile were observed among four type suppositories. $T_{max}$ of APAP-PEG and APAP-WH suppositories were 90 and 60 minutes, respectively, in hollow types. APAP-WH hollow type suppositories demonstrated fast absorption rates of APAP as compared with those of APAP-PEG suppositories. No burst effect was observed from APAP-WH suppository in contrast to APAP conventional type suppository, whereas AUCs of all the suppositories were similar. APAP-WH hollow type suppository may be an useful dosage form for hospital use.

• YAKHAK HOEJI
• /
• v.40 no.4
• /
• pp.400-410
• /
• 1996

In oder to develop the controlled release of drugs from the suppositories, in vitro drug release and in vivo absorption in rabbits were investigated. Various suppo sitory forms with hollow cavities, into which drugs in the form of fine powder or solid dispersion system(SDS) could be placed, were utilized. The oleaginous Witepsol H-15 (WH-15) as a base, and indomethacin (IDM) of a very slightly soluble drug and propranolol-HCL (PPH) of a very soluble drug were employed as model drugs. The in vitro drug release showed that the cumulative release amount of PPH from PPH-(methylcellulose) MC-SDS and PPH-(ethylcellulose) EC-SDS hollow type suppositories reached 40% and 12% in 6 hrs,respectively. On the other hand, the drug release for a conventional suppository was 80% in 6 hrs. For the IDM suppositories,the cumulative drug release from IDM-(polyvinylpyrrolidone) PVP-SDS hollow type suppositories reached 99% in 24 hrs, whereas that from a conventional suppository reached 85%. An in vivo experiment with rabbits showed that IDM-PVP-SDS hollow type suppository delayed the absorption of IDM, significantly. The $t_{max},\;C_{max}\;and\;AUC_{0{\to}8}$ of IDM-PVP-SDS suppository were 60 min, 12.12${\mu}g$/ml and 2657${\mu}g$/ml/min, respectively. The $t_{max},\;C_{max}\;and\;AUC_{0{\to}8}$ of controlled group were 20 min, 15.49${\mu}g$/ml and 2190${\mu}g$/ml/min, respectively.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.177-177
• /
• 1994

좌제중에서 OMZ의 분해는 1차 반응적이었으며, 안정화제로서는 arginine이 가장 좋아서 arginine을 10 mg 첨가한 Witepsol H15 좌약과 PEG 4000좌약의 분해속도 상수는 각각. 3.89$\times$10-3day$^{-1}$, 8.67$\times$$10^{-3}$ day$^{-1}$이어서, arginine 비첨가 Witepsol Hl5기제 (k = 00.11 day$^{-1}$, PEG 4000기제( k = 0.48 day$^{-1}$)의 경우보다 훨씬 양호하였으며, 35$^{\circ}C$, 75%RH에서 장기보존시험 결과 Witepsol H15 좌제와 PEG 4000 기제는 각각 k = 3.63$\times$$10^{-4}$ day$^{-1}$, t190% = 291 8 days와 k = 3.69$\times$$10^{-4}$ day$^{-1}$ 및 t90% = 282.1 days이었으며, 좌제로부터 약물의 용출에 미치는 영향은 arginine의 첨가, 원료약품 입자의 미세화, 적절한 계면활성제의 첨가 그리고 지용성 기제량의 감소등으로서 이들은 약물의 용출을 증가시켰다. 실험한 좌약의 bioavailability는 경구용 캅셀이 17%, 지용성좌제 44.9%, 수용성좌제 41.0%로서 좌제가 유의성 있게 높았으며(p<0.01), 지용성좌제에 SLS나 EDTA를 첨가하였을 때에는 각각 29.7%, 32.7%로서 이들을 첨가하지 않았을 때 보다 유의성 있게 낮았다(p<0.01). 또한 직장점막 자극시험결과 부작용을 관찰할 수 없었으며 간초회통과 회피율은 수용좌제에서 28.9%, 지용성좌제에서 33.6%로 나타나서 OMZ의 투여경로는 직장좌제가 유용한 한가지 투여방법이 될 것임을 시사하였다.

• YAKHAK HOEJI
• /
• v.43 no.2
• /
• pp.150-159
• /
• 1999

Hollow type suppositories inserted polyvinyl alcohol (PVA) hydrogel capsule containing propranolol·HCI (PPH) were prepared using different bases, polyethylene glycol (PEG), Witepsol H-15 (WH-15) and Witepsol W-35 (WW-35) to improve the controlled release of PPH. The release of PPH from the hollow type suppository inserted PVA hydrogel capsule was retarded than that from PEG, WH-15, or WW-35 hollow type suppositories in rat rectal cavity. When the suppositories were administered to rats, the controlled release of PPH was proved by the plasma concentration-time-profiles of PPH. No significant difference (p〈0.05) among the three different hollow type suppositories was observed in terms of AUC and MRT of PPH. WH-15 hollow type suppository inserted 12% of PVA hydrogel capsule caused irritation to rat rectal mucosa. However, the WH-15 hollow type suppository inserted PVA hydrogel capsule caused no severe irritation on rectal mucosa. The application of the hollow type suppositories using PVA in sustained rectal delivery of drugs might be feasible.

• YAKHAK HOEJI
• /
• v.37 no.5
• /
• pp.427-436
• /
• 1993

The pharmacokinetics and relationship between in vitro dissolution and in vivo fraction absorbed were investigated after intravenous(iv) injection of omeprazole(OMZ), oral administration of OMZ capsules and rectal administration of 8 types of suppositories. The plasma concentration of OMZ (C$_{p}$)-time (t) curve after iv. administration fitted a two-compartment open model and the equation which best fitted the pharmacokinetics of OMZ was $C_{p}$ = 13.936 $e^{-8.78t}$+2.973 $e^{-0.716t}$. The bioavailabilities of OMZ in Witepsol H15 base (Supp-2) and PEG 4000 base (Supp-6) suppositories were 40.7% and 33.4%, respectively, which are higher(p<0.001) than 13% of oral administration of capsule. The avoidance fractions of the first-pass metabolism for Supp-2 and Supp-6 suppositiories were 31.8% and 23.4%, respectively, suggesting that the rectal application of OMZ may be a more adequate route of administration than oral one.